Share This Page
Drug Price Trends for NDC 24979-0112
✉ Email this page to a colleague
Average Pharmacy Cost for 24979-0112
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 24979-0112
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| FENOFIBRIC ACID 135MG CAP,EC | Golden State Medical Supply, Inc. | 24979-0112-07 | 90 | 70.15 | 0.77944 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 24979-0112
Introduction
The pharmaceutical landscape continually evolves with emerging therapies, patent statuses, regulatory shifts, and market dynamics profoundly influencing drug valuation. This analysis provides a comprehensive overview of the market positioning, competitive landscape, and price trajectories for the drug identified by the National Drug Code (NDC) 24979-0112, facilitating strategic decision-making for stakeholders ranging from manufacturers to healthcare payers.
Drug Profile and Regulatory Status
NDC 24979-0112 pertains to [Specific Drug Name] — a [drug class or therapeutic indication if available]. As per the latest FDA records, this medication has achieved [approval status: e.g., full approval, accelerated approval, or orphan designation], enabling it to penetrate the outpatient, hospital, and specialty markets.
Its active ingredient, dosage form, and administration route position it within the [specific therapeutic area, e.g., oncology, cardiology, neurologic disorders] market. Currently, patent protection remains [status: active, nearing expiry, or expired], critically impacting future pricing strategies and market entry.
Market Dynamics and Competitive Landscape
Market Size and Growth Trends
The targeted therapeutic segment exhibits a compound annual growth rate (CAGR) of approximately [X]% over the last [Y] years, driven by rising prevalence of [relevant disease or condition] and expanding access to advanced therapies. The global market valuation is estimated at $[Z] billion in [latest year], projected to reach $[A] billion by [future year], indicating robust growth prospects.
Existing Competition
The competitive environment includes [number] major players such as [companies], with key differentiators being [mechanism of action, formulation, delivery system]. Generic versions or biosimilar entrants are expected to influence pricing, especially ahead of patent expiration, estimated around [date].
[If applicable], the drug faces competition from [alternative therapies, biologics, biosimilars], which may impact market share and pricing power.
Pricing Trends and Reimbursement Landscape
Historically, drugs in this segment have experienced [trend: stable, rising, or declining] pricing, contingent on factors such as:
- Regulatory approvals and shifts in reimbursement policies.
- Payer negotiations, with payers exerting pressure for cost containment.
- Market penetration and prescriber preferences.
Recent Medicare and Medicaid policy adjustments have been favoring value-based arrangements, influencing net prices downward or encouraging alternative payment models.
Price Projections Analysis
Historical Pricing Data
Current wholesale acquisition cost (WAC) for [Drug Name] stands at approximately $[X] per [unit/dose], with average pharmacy retail prices around $[Y]. Over the previous [Y] years, prices have shown [trend: increase/decrease/stability], reflecting factors such as competition, regulatory change, and market acceptance.
Forecasting Methodology
Price projections employ a multi-factorial model, integrating:
- Patent lifecycle stage.
- Expected biosimilar/generic market entry impacting prices.
- Regulatory approvals or label expansions.
- Market adoption rates influenced by prescriber and patient preferences.
- External factors including inflation and healthcare policy reforms.
Projected Price Trajectory (Next 3-5 Years)
Based on current trends and market intelligence, [Drug Name] is projected to experience:
- [Year 1]: Stabilization or slight decrease of [X]% in net prices due to imminent generic competition.
- [Year 2-3]: Potential steep decline of [Y]%–[Z]% in net prices post-patent expiry.
- [Year 4-5]: Market saturation with biosimilars or generics could drive prices to $[A]–$[B] range, depending on market segmentation and payer negotiations.
In the absence of biosimilar competition or regulatory shifts, prices could sustain at current or marginally reduced levels, emphasizing the importance of patent life and market adoption nuances.
Market Entry and Pricing Strategies
Manufacturers seeking to enter this segment should consider:
- Early biosimilar entry, leveraging patent expiry dates.
- Flexible pricing models, including value-based or outcome-based contracts.
- Enhanced market access initiatives directed at payers and providers.
- Innovative formulations or delivery systems to differentiate from existing therapies.
Conversely, established market players must navigate cost containment policies and evolving reimbursement landscapes to sustain profitability.
Key Risks and Opportunities
Risks
- Patent cliff and biosimilar proliferation could lead to substantial price erosion.
- Regulatory uncertainties or policy changes might constrain pricing flexibility.
- Market perception shifts favoring alternative treatments.
Opportunities
- Expansion into new indications or formulations can diversify revenue streams.
- Strategic alliances with biosimilar manufacturers.
- Investment in patient support programs to enhance market share.
Conclusion
The drug identified by NDC 24979-0112 occupies a significant position within its therapeutic domain, with market dynamics heavily influenced by patent status, competition, and reimbursement policies. While near-term prospects suggest price stability, upcoming patent expiration and biosimilar development present substantial pricing and market share challenges and opportunities.
Stakeholders should engage proactively in strategic planning, emphasizing early market entry strategies, flexible pricing approaches, and diversified indication development to optimize profitability and market positioning in the evolving pharmaceutical landscape.
Key Takeaways
- The current market for [Drug Name] is characterized by steady demand and moderate pricing margins, with an impending impact from biosimilar competition post-patent expiry.
- Price trajectories indicate significant reductions commencing [X] years ahead, emphasizing the importance of timing in market entry or investment decisions.
- Evolving healthcare policies favoring value-based care models may influence future pricing and reimbursement strategies.
- Diversification through indication expansion and formulation innovation can mitigate revenue risks associated with patent expiration.
- Strategic collaborations with biosimilar manufacturers or payers could enhance market stability and profit margins.
FAQs
-
What is the current patent status of NDC 24979-0112?
The patent is active until [date], with generic biosimilar competition anticipated shortly thereafter, likely leading to significant price reductions. -
How does patent expiry affect pricing for this drug?
Typically, patent expiry invites biosimilar or generic entrants, precipitating competitive pricing and substantially lowering net prices. -
What are the primary factors influencing future prices?
Patent status, market competition, regulatory changes, reimbursement policies, and prescriber adoption are key determinants. -
Are there opportunities for new entrants in this segment?
Yes; new collaborations, innovative formulations, or expanded indications can open pathways to market entry, especially post-patent expiry. -
How can manufacturers prepare for impending market shifts?
By planning early biosimilar development, engaging in value-based contracting, and expanding indications before patent expiration, companies can sustain profitability.
References
- [Source detailing FDA approval and patent information]
- [Market research reports on therapeutic segment growth]
- [Pricing trend analyses and reimbursement policy updates]
- [Industry insights on biosimilar entry timelines]
- [Regulatory guidance documents relevant to biosimilar approval]
Note: Specific data points should be referenced from the latest market intelligence and regulatory filings at the time of strategic decision-making.
More… ↓
